DEF 14A: Interpace Biosciences Sets Date for Virtual Annual Stockholders Meeting

Interpace Biosciences will hold its annual stockholders meeting virtually on November 12, 2024, to vote on the ratification of its independent accounting firm and other business matters.

Summary

• Interpace Biosciences, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on November 12, 2024, at 4:00 p.m. Eastern Time.
• Stockholders of record as of September 18, 2024, are entitled to vote at the meeting.
• The meeting will include a vote on the ratification of the appointment of EisnerAmper, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The board recommends a vote FOR the ratification of EisnerAmper's appointment.
• Stockholders can attend, vote, and submit questions online at www.virtualshareholdermeeting.com/IDXG2024.
• The company is using the Notice and Access method to provide proxy materials to stockholders, with the mailing of the Notice beginning on or about October 1, 2024.
• As of the record date, there were 4,404,795 shares of common stock and 47,000 shares of Series B convertible preferred stock outstanding.
• Two Series B Preferred Stock stockholders control 64% of the outstanding shares of common stock on an as-converted basis.
• The board consists of five members divided into three classes.
• Each non-employee director received an annual fee of $40,000 in 2023, with additional fees for committee chairs.
• Thomas W. Burnell serves as President, Chief Executive Officer, and Chairman of the Board.
• Christopher McCarthy was appointed Chief Financial Officer on July 24, 2023.
• The company's executive compensation program includes base salary, annual cash incentives, and equity incentives.
• The company has established a whistleblower hotline for reporting concerns regarding corporate compliance matters.

Sentiment

Score: 7

Explanation: The document is generally positive and informative, focusing on corporate governance and shareholder engagement. The tone is professional and optimistic, reflecting a standard communication for an annual meeting.

Positives

• The company is using the latest technology to increase access, improve communication, and obtain cost savings for its stockholders by holding a virtual meeting.
• Stockholders have the ability to attend, vote, and submit questions shortly before and during the virtual meeting from any location via the Internet.
• The Board recommends a vote FOR Proposal No. 1, the ratification of appointment of EisnerAmper as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The company maintains a whistleblower hotline for reporting concerns regarding corporate compliance matters in a confidential or anonymous manner.

Future Outlook

The document does not contain specific forward-looking statements regarding financial performance or business strategy beyond the details of the upcoming annual meeting.

Management Comments

• Thomas W. Burnell, President, Chief Executive Officer and Chairman of the Board: 'We are delighted to have you as a stockholder of Interpace, and we thank you for your ongoing support.'
• Thomas W. Burnell, President, Chief Executive Officer and Chairman of the Board: 'We are pleased to use the latest technology to increase access, to improve communication and to obtain cost savings for our stockholders and the Company.'

Industry Context

The move to a virtual annual meeting reflects a broader trend in corporate governance to leverage technology for increased accessibility and cost efficiency. Many companies are adopting virtual or hybrid meeting formats to engage with a wider range of stockholders and reduce the expenses associated with physical meetings.

Comparison to Industry Standards

• The director compensation structure, with base fees and additional compensation for committee chairs, is fairly standard among publicly traded companies of similar size.
• The executive compensation packages, including base salary, bonus potential, and equity incentives, are typical for companies in the biotechnology and diagnostics industries.
• Companies like Exact Sciences, Guardant Health, and Myriad Genetics also utilize similar compensation strategies to attract and retain executive talent.
• The ownership structure, with significant control held by private equity firms (Ampersand and 1315 Capital), is not uncommon for companies that have received substantial private equity investment.

Management Changes

Related Party Transactions

• On August 31, 2022, the Company and its subsidiary, Interpace Pharma Solutions, Inc. (IPS), entered into an Asset Purchase Agreement (the Purchase Agreement) with Flagship Biosciences, Inc. (Flagship) pursuant to which Flagship agreed to (i) acquire substantially all of the assets of IPS used in IPSs business and (ii) assume and pay certain liabilities related to the purchased assets as set forth in the Purchase Agreement (collectively, the Asset Sale).
• An affiliate of Ampersand Management LLC and an affiliate of BroadOak Capital Partners have each provided equity financing to Flagship, collectively own a majority of Flagships outstanding equity securities and are represented on its Board of Directors.
• The affiliate of Ampersand Management LLC also owns 28,000 shares of the Companys Series B Preferred Stock, convertible into 4,666,666 shares of the Companys common stock pursuant to that certain Securities Purchase and Exchange Agreement dated January 10, 2020.
• The affiliate of Ampersand Management LLC has designated two directors to the Companys Board of Directors, Robert Gorman and Vijay Aggarwal.
• In addition, an affiliate of BroadOak Capital Partners provided the Company a term loan in the aggregate principal amount of $8,000,000 pursuant to that certain Loan and Security Agreement dated October 29, 2021 and a Convertible Note which converted into a term loan advance in the aggregate amount of $2,000,000.
• The total purchase price for the Asset Sale was determined following a sales process conducted by the Company and its advisors and an arms length negotiation between Flagship and the Company.
• The Asset Sale was approved by a majority of the disinterested directors of the Company.

Stakeholder Impact

• Stockholders are encouraged to participate in the virtual Annual Meeting and vote on the proposals.
• Employees are subject to the company's Code of Business Conduct.
• The company's executive compensation program is designed to align the interests of management with those of the stockholders.
• The company has established a whistleblower hotline for reporting concerns regarding corporate compliance matters.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• Stockholders can attend the virtual Annual Meeting on November 12, 2024.
• The company will file the voting results with the SEC within four business days following the Annual Meeting.
• The company will continue to engage with stockholders and provide updates on its business and financial performance.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Interpace Biosciences, EisnerAmper, Board of Directors, Voting, Corporate Governance, Executive Compensation, Audit Committee